

**JOINT COMMITTEE ON FINANCIAL SERVICES
2025-2026 (194th) BILL SUMMARY**

Bill No: H1307

Title: AN ACT RELATIVE TO TESTING FOR FACTOR V LEIDEN

Sponsor: Rep. Daniel J. Ryan (*Boston*)

Hearing Date: June 24, 2025

Reporting Deadline: August 23, 2025

Prior History:

2023-24 (H1134): Ordered to a House Study

2021-22 (H1193): Ordered to a House Study

2019-20 (H1097): Ordered to a House Study

Similar Matters: None

CURRENT LAW:

M.G.L. c. 175 Insurance § 47W Outpatient services; hormone replacement therapy for peri and post menopausal women; contraceptive services; approved prescription contraceptive drugs or devices; exception

SUMMARY:

This bill directs an individual, general, blanket, or group policy of health, accident, and sickness insurance to provide coverage for a blood test to screen for Factor V Leiden before a pharmacological contraceptive method is prescribed. Factor V Leiden is caused by a mutation in the F5 gene, which provides instructions for making factor V, a protein involved in blood clotting. The mutation makes factor V more resistant to being broken down by activated protein C (APC), an anticoagulant. This leads to an increased risk of blood clots forming. Most people with Factor V Leiden do not experience any symptoms.